Current status and reflections on immunotherapy and targeted therapy for unresectable biliary tract cancer
10.16139/j.1007-9610.2025.06.14
- VernacularTitle:不可切除胆道恶性肿瘤免疫及靶向治疗的现状与思考
- Author:
Liqin YU
;
Xiaoyu YAN
;
Puxiongzhi WANG
;
Wei WANG
;
Jian WANG
- Publication Type:Journal Article
- From:
Journal of Surgery Concepts & Practice
2025;30(6):544-550
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract cancer (BTC) represents a group of highly malignant solid tumors with a five-year survival rate of only 10%. For patients with unresectable BTC, gemcitabine combined with cisplatin has been the conventional first-line treatment regimen. With the remarkable efficacy of immunotherapy and targeted therapy observed in other solid tumors, numerous studies have investigated their potential in unresectable BTC. This article provides an overview of the current status of targeted and immunotherapeutic approaches for unresectable BTC, with a focus on research advancements in immune checkpoint inhibitor (ICI) and targeted agents against fibroblast growth factor receptor(FGFR), isocitrate dehydrogenase(IDH), and human epidermal growth factor receptor 2(HER2), as well as future trends in immunotherapy and targeted therapy, aiming to contribute to the development of more effective treatment strategies.
